198 related articles for article (PubMed ID: 28814143)
1. LY3045697: Results from two randomized clinical trials of a novel inhibitor of aldosterone synthase.
Sloan-Lancaster J; Raddad E; Flynt A; Jin Y; Voelker J; Miller JW
J Renin Angiotensin Aldosterone Syst; 2017; 18(3):1470320317717883. PubMed ID: 28814143
[TBL] [Abstract][Full Text] [Related]
2. Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2).
Bogman K; Schwab D; Delporte ML; Palermo G; Amrein K; Mohr S; De Vera Mudry MC; Brown MJ; Ferber P
Hypertension; 2017 Jan; 69(1):189-196. PubMed ID: 27872236
[TBL] [Abstract][Full Text] [Related]
3. Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers.
Freeman MW; Bond M; Murphy B; Hui J; Isaacsohn J
Hypertens Res; 2023 Jan; 46(1):108-118. PubMed ID: 36266539
[TBL] [Abstract][Full Text] [Related]
4. Aldosterone synthase inhibition in humans.
Azizi M; Amar L; Menard J
Nephrol Dial Transplant; 2013 Jan; 28(1):36-43. PubMed ID: 23045428
[TBL] [Abstract][Full Text] [Related]
5. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism.
Amar L; Azizi M; Menard J; Peyrard S; Watson C; Plouin PF
Hypertension; 2010 Nov; 56(5):831-8. PubMed ID: 20837883
[TBL] [Abstract][Full Text] [Related]
6. Rhesus monkey model for concurrent analyses of in vivo selectivity, pharmacokinetics and pharmacodynamics of aldosterone synthase inhibitors.
Cai TQ; Stribling S; Tong X; Xu L; Wisniewski T; Fontenot JA; Struthers M; Akinsanya KO
J Pharmacol Toxicol Methods; 2015; 71():137-46. PubMed ID: 25304940
[TBL] [Abstract][Full Text] [Related]
7. Discovery of N-[5-(6-Chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects.
Papillon JP; Lou C; Singh AK; Adams CM; Ksander GM; Beil ME; Chen W; Leung-Chu J; Fu F; Gan L; Hu CW; Jeng AY; LaSala D; Liang G; Rigel DF; Russell KS; Vest JA; Watson C
J Med Chem; 2015 Dec; 58(23):9382-94. PubMed ID: 26540564
[TBL] [Abstract][Full Text] [Related]
8. Dihydrobenzisoxazole-4-one compounds are novel selective inhibitors of aldosterone synthase (CYP11B2) with in vivo activity.
Meyers K; Cogan DA; Burke J; Arenas R; Balestra M; Brown NF; Chen Z; Cerny MA; Clifford HE; Colombo F; Fader L; Frederick KS; Guo X; Goldberg D; Hornberger KR; Kugler S; Lord J; Marshall DR; Moss N; Parmentier JH; Richman JR; Schmenk J; Weldon SM; Yu M; Zhang M
Bioorg Med Chem Lett; 2018 Mar; 28(5):979-984. PubMed ID: 29254646
[TBL] [Abstract][Full Text] [Related]
9. Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects.
Ménard J; Rigel DF; Watson C; Jeng AY; Fu F; Beil M; Liu J; Chen W; Hu CW; Leung-Chu J; LaSala D; Liang G; Rebello S; Zhang Y; Dole WP
J Transl Med; 2014 Dec; 12():340. PubMed ID: 25491597
[TBL] [Abstract][Full Text] [Related]
10. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial.
Calhoun DA; White WB; Krum H; Guo W; Bermann G; Trapani A; Lefkowitz MP; Ménard J
Circulation; 2011 Nov; 124(18):1945-55. PubMed ID: 21986283
[TBL] [Abstract][Full Text] [Related]
11. The effects of aldosterone synthase inhibition on aldosterone and cortisol in patients with hypertension: a phase II, randomized, double-blind, placebo-controlled, multicenter study.
Andersen K; Hartman D; Peppard T; Hermann D; Van Ess P; Lefkowitz M; Trapani A
J Clin Hypertens (Greenwich); 2012 Sep; 14(9):580-7. PubMed ID: 22947355
[TBL] [Abstract][Full Text] [Related]
12. CYP11B2 inhibitor dexfadrostat phosphate suppresses the aldosterone-to-renin ratio, an indicator of sodium retention, in healthy volunteers.
Mulatero P; Groessl M; Vogt B; Schumacher C; Steele RE; Brooks A; Hossack S; Brunner HR
Br J Clin Pharmacol; 2023 Aug; 89(8):2483-2496. PubMed ID: 36914591
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys.
Martin RE; Aebi JD; Hornsperger B; Krebs HJ; Kuhn B; Kuglstatter A; Alker AM; Märki HP; Müller S; Burger D; Ottaviani G; Riboulet W; Verry P; Tan X; Amrein K; Mayweg AV
J Med Chem; 2015 Oct; 58(20):8054-65. PubMed ID: 26403853
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Novel Pyrazole-Based Selective Aldosterone Synthase (CYP11B2) Inhibitors: A New Template to Coordinate the Heme-Iron Motif of CYP11B2.
Sakakibara R; Sasaki W; Onda Y; Yamaguchi M; Ushirogochi H; Hiraga Y; Sato K; Nishio M; Egi Y; Takedomi K; Shimizu H; Ohbora T; Akahoshi F
J Med Chem; 2018 Jul; 61(13):5594-5608. PubMed ID: 29878770
[TBL] [Abstract][Full Text] [Related]
15. Progress towards clinically useful aldosterone synthase inhibitors.
Cerny MA
Curr Top Med Chem; 2013; 13(12):1385-401. PubMed ID: 23688131
[TBL] [Abstract][Full Text] [Related]
16. Heteroatom insertion into 3,4-dihydro-1H-quinolin-2-ones leads to potent and selective inhibitors of human and rat aldosterone synthase.
Grombein CM; Hu Q; Rau S; Zimmer C; Hartmann RW
Eur J Med Chem; 2015 Jan; 90():788-96. PubMed ID: 25528333
[TBL] [Abstract][Full Text] [Related]
17. A novel aldosterone synthase inhibitor ameliorates mortality in pressure-overload mice with heart failure.
Furuzono S; Meguro M; Miyauchi S; Inoue S; Homma T; Yamada K; Tagawa YI; Nara F; Nagayama T
Eur J Pharmacol; 2017 Jan; 795():58-65. PubMed ID: 27915044
[TBL] [Abstract][Full Text] [Related]
18. Selectivity of BI 689648, a Novel, Highly Selective Aldosterone Synthase Inhibitor: Comparison with FAD286 and LCI699 in Nonhuman Primates.
Weldon SM; Cerny MA; Gueneva-Boucheva K; Cogan D; Guo X; Moss N; Parmentier JH; Richman JR; Reinhart GA; Brown NF
J Pharmacol Exp Ther; 2016 Oct; 359(1):142-50. PubMed ID: 27481775
[TBL] [Abstract][Full Text] [Related]
19. Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance.
Stowasser M; Bachmann AW; Huggard PR; Rossetti TR; Gordon RD
J Clin Endocrinol Metab; 2000 Jun; 85(6):2160-6. PubMed ID: 10852446
[TBL] [Abstract][Full Text] [Related]
20. Structure-Activity Relationships, Pharmacokinetics, and in Vivo Activity of CYP11B2 and CYP11B1 Inhibitors.
Papillon JP; Adams CM; Hu QY; Lou C; Singh AK; Zhang C; Carvalho J; Rajan S; Amaral A; Beil ME; Fu F; Gangl E; Hu CW; Jeng AY; LaSala D; Liang G; Logman M; Maniara WM; Rigel DF; Smith SA; Ksander GM
J Med Chem; 2015 Jun; 58(11):4749-70. PubMed ID: 25953419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
